FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Men with Prostate Cancer Undergoing ADT

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in men receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. Men receiving ADT are at high risk for developing fractures, including vertebral fractures, which can cause paralysis. "Bone loss [...]

Genetics & Calcium Might Increase Risk for Prostate Cancer In the African-American Men

A study by at Wake Forest Baptist Medical Center in Winston-Salem N.C., Keck School of Medicine at the University of Southern California (USC) and the Cancer Prevention Institute of California suggests that a high intake of calcium causes prostate cancer among African-American men who are genetically good absorbers of the mineral. According to Gary G. [...]

The Impact of Hypertriglyceridemia On Prostate Cancer Development in Men Over 60 Years

An interesting, but it makes sense type of study, was discussed about the relationship between high levels of triglycerides (TG) and the development of prostate cancer, including more aggresive prostate cancer. It of course follows suite that prostate cancer diagnosed with higher gleason scores (more aggressive) leads to more advanced prostate cancer. This study which [...]

Morbidity and Treatment Regret in Men with Advanced Prostate Cancer

The question of today’s post is do men with advanced prostate cancer develop treatment regrets concurrent to their development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation)? To answer this question researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry [...]

Go to Top